ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO727

Computational Drug Screening Identifies the Androgen Receptor Antagonist Flutamide as a Potential Treatment Option for Polycystic Kidney Disease

Session Information

Category: Genetic Diseases of the Kidneys

  • 1001 Genetic Diseases of the Kidneys: Cystic


  • Perco, Paul, Medical University Innsbruck, Innsbruck, Austria
  • Leierer, Johannes, Medical University Innsbruck, Innsbruck, Austria
  • Rudnicki, Michael, Medical University Innsbruck, Innsbruck, Austria
  • Mayer, Gert J., Medical University Innsbruck, Innsbruck, Austria

Treatment options for patients with autosomal dominant polycystic kidney disease (ADPKD) are limited and novel therapies are needed. A key hallmark of ADPKD is enhanced tubular epithelial cell proliferation.


We constructed a network-based molecular model of ADPKD using ADPKD-associated molecular features from scientific literature, the OMIM database, clinical trials on ADPKD, and a human ADPKD transcriptomics dataset. We computationally screened compound libraries with the ADPKD molecular model using data from the Connectivity Map and a constructed library of literature-based drug mechanism of action molecular models. We finally evaluated the impact of top-ranked compounds on cell viability and proliferation in two ADPKD cell lines and HK2 cells.


Five compounds - flutamide, mifepristone, spironolactone, troglitazone, and vorinostat - were identified in the computational drug screen being capable of inversing the ADPKD gene signature and showing significant positive overlap with the ADPKD molecular model. Four compounds had a significant negative impact on cell viability in ADPKD cell lines as compared to treated HK2 cells. Flutamide had the strongest impact on ADPKD cell viability (65.4% in WT9-7, 67.8% in WT9-12, 92.0% in HK2 cells). Flutamide on top significantly reduced cell proliferation in ADPKD cells (41.1% in WT9-7 and 41.9% in WT9-12) as compared to HK2 cells (92.8%).


Flutamide significantly hampers cell viability and cell proliferation of ADPKD cells and warrants follow-up studies to investigate its potential as novel treatment option for patients with ADPKD.

The impact of flutamide on cell viability and cell proliferation in the two ADPKD cell lines WT9-7 and WT9-12 as well as in control human renal proximal tubular (HK2) cells is displayed. Data are presented as mean and standard deviation


  • Government Support - Non-U.S.